Clinical Trials Logo

Lymphoma, Large-Cell, Diffuse clinical trials

View clinical trials related to Lymphoma, Large-Cell, Diffuse.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT00514722 Terminated - Multiple Myeloma Clinical Trials

Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies

Start date: October 2002
Phase: N/A
Study type: Interventional

This is a pilot study designed to evaluate the safety and feasibility of performing umbilical cord blood transplants in adults with high-risk hematopoietic malignancies. A novel myeloablative preparative regimen will be used. One, up to a maximum of three cord blood units will be administered to facilitate engraftment.

NCT ID: NCT00511043 Terminated - Clinical trials for Lymphoma, Large-Cell, Diffuse

PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma

Start date: November 2005
Phase: Phase 2
Study type: Interventional

This is a phase II open label study to assess the efficacy and safety of PTK787/ZK222584 in adults with relapsed or refractory diffuse large cell lymphoma (DLCL). All subjects will receive PTK787/ZK222584. Subjects who tolerate the study target dose of 1250mg will remain on that dose until study completion at 12 months or until disease progression, unacceptable toxicity, withdrawal of consent or non-compliance with the protocol requirement.

NCT ID: NCT00498914 Terminated - Clinical trials for Lymphoma, Large-Cell, Diffuse

Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

Start date: June 2007
Phase: Phase 2
Study type: Interventional

A study in subjects with a type of B cell lymphoma (DLBCL)to evaluate the response rate, efficacy, safety and tolerability of YM155

NCT ID: NCT00322218 Terminated - Clinical trials for Lymphoma, Large Cell, Diffuse

Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.

Start date: May 2006
Phase: Phase 3
Study type: Interventional

This study treats patients with diffuse large B-cell lymphoma whose disease is in complete remission due to previous treatment with Cyclophosphamide Doxorubicin hydrochloride Vincristine Prednisolone- Rituximab (CHOP-R). Half of the patients received Zevalin and the other half receive no further anti-cancer treatment. The two patient groups compared to determine if Zevalin given after CHOP-R therapy provides greater benefits than receiving no additional anti-cancer therapy after CHOP-R.

NCT ID: NCT00135499 Terminated - Clinical trials for Lymphoma, Large-Cell, Diffuse

R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma

Start date: October 16, 2001
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP) plus rituximab in comparison to cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) plus rituximab in patients aged from 60 to 65 years with non-previously treated diffuse large B-cell lymphoma as measured by the event-free survival. The goal is to obtain a 10% increase of event-free survival at 3 years.